Arovella Therapeutics (ASX:ALA) has reported new preclinical data that strengthens the case for its engineered immune cell platform, demonstrating sustained and enhanced killing of pancreatic and gastric cancer cells in laboratory studies.
Engineered immune cells show striking durability against hard to treat cancers
April 1, 2026 Australian Biotech
Latest Video
New Stories
-
The 'Dispatched' Week in Review' Podcast - 15 May
May 15, 2026 - - Podcast -
New Zealand still falling behind on access to modern medicines
May 15, 2026 - - Latest News -
AusBiotech welcomes Budget's creation of new National Resilience and Science Council
May 15, 2026 - - Latest News -
Minister fired the starting gun in March, he flung the door open in Budget week
May 14, 2026 - - Latest News -
There are a number of reasons to criticise the minister on the PBS, but he is right to be annoyed about this
May 14, 2026 - - Latest News -
Long-term study finds continuing Mounjaro helps maintain weight loss
May 14, 2026 - - Latest News -
Frustrated minister encourages an early negotiation of new agreements
May 14, 2026 - - Latest News
